论文部分内容阅读
目的对依达拉奉联合疏血通治疗急性缺血性脑卒中的临床效果进行对比分析。方法选取2012年5月至2014年5月东莞市黄江医院收治的急性缺血性脑卒中患者96例,按入院时间随机均分为实验组和对照组,每组48例。对照组采用疏血通治疗,实验组在此基础上采用依达拉奉联合疏血通治疗。通过比较两组患者治疗前后的神经功能缺损评分变化以观察依达拉奉联合疏血通治疗急性缺血性脑卒中的临床疗效。结果两组治疗神经功能缺损评分均有下降,但实验组治疗后下降程度明显大于对照组(P<0.05)。实验组治疗后有效率为93.8%,明显高于对照组的75.0%(P<0.05)。结论依达拉奉联合疏血通治疗急性缺血性脑卒中具有很好的临床疗效,安全性高,值得临床推广。
Objective To compare the clinical effects of Edaravone and Shuxuetong in the treatment of acute ischemic stroke. Methods 96 cases of acute ischemic stroke admitted to Huangjiang Hospital of Dongguan City from May 2012 to May 2014 were randomly divided into experimental group and control group according to the time of admission, and each group had 48 cases. The control group was treated with Shuxuetong, and the experimental group was treated with edaravone and Shuxuetong on the basis of this. By comparing the two groups of patients before and after treatment of neurological deficit score changes in order to observe the Edaravone combined Shuxuetong the clinical efficacy of acute ischemic stroke. Results The score of neurological deficit in both groups decreased, but the decrease in experimental group after treatment was significantly greater than that in control group (P <0.05). The effective rate of the experimental group after treatment was 93.8%, which was significantly higher than that of the control group (75.0%, P <0.05). Conclusion Edaravone and Shuxuetong have good clinical curative effect in treating acute ischemic stroke, which is safe and worthy of clinical promotion.